HIMA Comments on the Revised Edition of the document 
"Medical Surveillance of Biotechnology Workers: 
Report of the CDC/NIOSH Ad Hoc Working Group on 
Medical Surveillance for Industrial Applications of Biotechnology." 
Presented at the Large-Scale Working Group meeting, June 29, 1982. 
My name is Timothy Henry. I'm Director of Biological Sciences for the 
Health Industry Manufacturers Association. HIMA Is a trade 
association that represents 266 medical device and diagnostic product 
manufacturers with some 570 operating divisions with names familiar to 
all of you. Last year these companies had aggregate sales of more than 
10 billion dollars. 
Biotechnology is an ever increasing factor in the plans of HIMA 
companies. Hybrldoma technology has already had an important and 
positive impact upon these companies. Recombinant DNA technology has 
not yet had a similar impact upon our companies, but it is obvious to 
all of us in the industry that our members will undoubtedly be using 
R-DNA in their everyday lab work. HIMA has established two Internal 
biotechnology interest groups — one on hybridomas and one on R-DNA 
issues — and we hope that these committees soon will be able to offer 
cogent and helpful comments on Issues before this working group or 
before RAC. The HIMA R-DNA committee was just formed and I have 
1 
1530] 
